Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -13.22% is 75% above its 5-year average of -51.87%, near the high end of its 5-year range (-114.39%–-9.75%).
25.73% above its 12-month average of -17.80%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.94%.
RETURN ON ASSETS (ROA)
-13.22%
RETURN ON ASSETS (ROA) AVG TTM
-17.80%
RETURN ON ASSETS (ROA) AVG 3Y
-57.37%
RETURN ON ASSETS (ROA) AVG 5Y
-51.87%
RETURN ON ASSETS (ROA) AVG 10Y
-56.26%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+25.73%
CURRENT VS 3Y AVG
+76.96%
CURRENT VS 5Y AVG
+74.51%
CURRENT VS 10Y AVG
+76.50%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+59.00%
vs the sector median at left
Monopar Therapeutics Inc.
Market Cap
$533.04M
Return on Assets (ROA)
-13.22%
TTM Avg
-17.80%
3Y Avg
-57.37%
5Y Avg
-51.87%
Market Cap
$531.98M
Return on Assets (ROA)
0.39%
TTM Avg
-16.14%
3Y Avg
-90.03%
5Y Avg
-84.55%
Market Cap
$531.52M
Return on Assets (ROA)
-124.45%
TTM Avg
-92.75%
3Y Avg
-98.77%
5Y Avg
-98.11%
Market Cap
$529.58M
Return on Assets (ROA)
-23.82%
TTM Avg
-68.22%
3Y Avg
-60.20%
5Y Avg
-44.39%
Market Cap
$538.01M
Return on Assets (ROA)
-34.82%
TTM Avg
-17.21%
3Y Avg
-15.93%
5Y Avg
-60.12%
Market Cap
$524.43M
Return on Assets (ROA)
-16.69%
TTM Avg
-61.13%
3Y Avg
-63.72%
5Y Avg
-100.27%
Market Cap
$519.25M
Return on Assets (ROA)
-17.40%
TTM Avg
-49.85%
3Y Avg
-45.66%
5Y Avg
-41.17%
Market Cap
$548.51M
Return on Assets (ROA)
-30.29%
TTM Avg
-86.87%
3Y Avg
-85.61%
5Y Avg
-77.02%
Market Cap
$516.76M
Return on Assets (ROA)
-42.15%
TTM Avg
-50.20%
3Y Avg
-44.84%
5Y Avg
-47.93%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $533.04M | -13.22% | -17.80% | -57.37% | -51.87% |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 0.39% | -16.14% | -90.03% | -84.55% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | -124.45% | -92.75% | -98.77% | -98.11% |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | -23.82% | -68.22% | -60.20% | -44.39% |
| ProKidney Corp. (PROK)vs › | $538.01M | -34.82% | -17.21% | -15.93% | -60.12% |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | -16.69% | -61.13% | -63.72% | -100.27% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -17.40% | -49.85% | -45.66% | -41.17% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | -30.29% | -86.87% | -85.61% | -77.02% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | -42.15% | -50.20% | -44.84% | -47.93% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | -20.89% | 7.49% | -5.84% | -12.60% |
ROA
-13.2%
ROE
-13.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -9.75% |
| 2024-12-31 | -25.85% |
| 2023-12-31 | -114.39% |
| 2022-12-31 | -79.50% |
| 2021-12-31 | -44.36% |
| 2020-12-31 | -37.37% |
| 2019-12-31 | -31.64% |
| 2018-12-31 | -44.11% |
| 2017-12-31 | -166.70% |
| 2016-12-31 | -40.95% |
| 2015-12-31 | -24.29% |
